AMGN vs. CYTK: A Head-to-Head Stock Comparison

Updated on July 7, 2025

Here’s a clear look at AMGN and CYTK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

AMGN’s market capitalization of 160.37 billion USD is substantially larger than CYTK’s 4.14 billion USD, indicating a significant difference in their market valuations.

With betas of 0.50 for AMGN and 0.59 for CYTK, both stocks show similar sensitivity to overall market movements.

Symbol	AMGN	CYTK
Company Name	Amgen Inc.	Cytokinetics, Incorporated
Country	US	US
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - General	Biotechnology
CEO	Robert A. Bradway	Robert I. Blum
Price	298.24 USD	34.66 USD
Market Cap	160.37 billion USD	4.14 billion USD
Beta	0.50	0.59
Exchange	NASDAQ	NASDAQ
IPO Date	June 17, 1983	April 30, 2004
ADR	No	No

Historical Performance

This chart compares the performance of AMGN and CYTK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

AMGN vs. CYTK: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

AMGN

92.94%

Drug Manufacturers - General Industry

Max: 95.59%
Q3: 76.92%
Median: 30.71%
Q1: 8.97%
Min: -14.85%

In the upper quartile for the Drug Manufacturers - General industry, AMGN’s Return on Equity of 92.94% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

CYTK

801.26%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

CYTK’s Return on Equity of 801.26% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

AMGN vs. CYTK: A comparison of their ROE against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Return on Invested Capital

AMGN

9.53%

Drug Manufacturers - General Industry

Max: 25.72%
Q3: 17.89%
Median: 11.47%
Q1: 9.39%
Min: 2.87%

AMGN’s Return on Invested Capital of 9.53% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.

CYTK

-49.75%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

CYTK has a negative Return on Invested Capital of -49.75%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

AMGN vs. CYTK: A comparison of their ROIC against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Net Profit Margin

AMGN

17.39%

Drug Manufacturers - General Industry

Max: 34.51%
Q3: 23.04%
Median: 14.73%
Q1: 11.78%
Min: 2.18%

AMGN’s Net Profit Margin of 17.39% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.

CYTK

-3,201.47%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

CYTK has a negative Net Profit Margin of -3,201.47%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

AMGN vs. CYTK: A comparison of their Net Profit Margin against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Operating Profit Margin

AMGN

21.82%

Drug Manufacturers - General Industry

Max: 40.70%
Q3: 28.90%
Median: 23.41%
Q1: 19.05%
Min: 16.13%

AMGN’s Operating Profit Margin of 21.82% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.

CYTK

-2,943.30%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

CYTK has a negative Operating Profit Margin of -2,943.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

AMGN vs. CYTK: A comparison of their Operating Margin against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	AMGN	CYTK
Return on Equity (TTM)	92.94%	801.26%
Return on Assets (TTM)	6.64%	-48.67%
Return on Invested Capital (TTM)	9.53%	-49.75%
Net Profit Margin (TTM)	17.39%	-3201.47%
Operating Profit Margin (TTM)	21.82%	-2943.30%
Gross Profit Margin (TTM)	63.00%	-1359.51%

Financial Strength

Current Ratio

AMGN

1.17

Drug Manufacturers - General Industry

Max: 1.67
Q3: 1.37
Median: 1.26
Q1: 0.87
Min: 0.39

AMGN’s Current Ratio of 1.17 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.

CYTK

5.99

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

CYTK’s Current Ratio of 5.99 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

AMGN vs. CYTK: A comparison of their Current Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Debt-to-Equity Ratio

AMGN

9.24

Drug Manufacturers - General Industry

Max: 2.95
Q3: 2.44
Median: 0.86
Q1: 0.68
Min: 0.09

With a Debt-to-Equity Ratio of 9.24, AMGN operates with exceptionally high leverage compared to the Drug Manufacturers - General industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

CYTK

-2.97

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

CYTK has a Debt-to-Equity Ratio of -2.97, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.

AMGN vs. CYTK: A comparison of their D/E Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Interest Coverage Ratio

AMGN

3.19

Drug Manufacturers - General Industry

Max: 27.46
Q3: 14.40
Median: 7.80
Q1: 4.07
Min: 1.67

In the lower quartile for the Drug Manufacturers - General industry, AMGN’s Interest Coverage Ratio of 3.19 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

CYTK

-6.14

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

CYTK has a negative Interest Coverage Ratio of -6.14. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

AMGN vs. CYTK: A comparison of their Interest Coverage against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	AMGN	CYTK
Current Ratio (TTM)	1.17	5.99
Quick Ratio (TTM)	0.88	5.99
Debt-to-Equity Ratio (TTM)	9.24	-2.97
Debt-to-Asset Ratio (TTM)	0.64	0.63
Net Debt-to-EBITDA Ratio (TTM)	3.92	-1.39
Interest Coverage Ratio (TTM)	3.19	-6.14

Growth

The following charts compare key year-over-year (YoY) growth metrics for AMGN and CYTK. These metrics are based on the companies’ annual financial reports.

Revenue Growth

AMGN vs. CYTK: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

AMGN vs. CYTK: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

AMGN vs. CYTK: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

AMGN

3.10%

Drug Manufacturers - General Industry

Max: 8.72%
Q3: 4.10%
Median: 3.34%
Q1: 1.89%
Min: 0.00%

AMGN’s Dividend Yield of 3.10% is consistent with its peers in the Drug Manufacturers - General industry, providing a dividend return that is standard for its sector.

CYTK

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

AMGN vs. CYTK: A comparison of their Dividend Yield against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Dividend Payout Ratio

AMGN

82.64%

Drug Manufacturers - General Industry

Max: 266.46%
Q3: 78.91%
Median: 60.27%
Q1: 43.74%
Min: 0.00%

AMGN’s Dividend Payout Ratio of 82.64% is in the upper quartile for the Drug Manufacturers - General industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

CYTK

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

AMGN vs. CYTK: A comparison of their Payout Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	AMGN	CYTK
Dividend Yield (TTM)	3.10%	0.00%
Dividend Payout Ratio (TTM)	82.64%	0.00%

Valuation

Price-to-Earnings Ratio

AMGN

27.04

Drug Manufacturers - General Industry

Max: 27.96
Q3: 25.84
Median: 18.32
Q1: 16.65
Min: 3.39

A P/E Ratio of 27.04 places AMGN in the upper quartile for the Drug Manufacturers - General industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

CYTK

-6.68

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

CYTK has a negative P/E Ratio of -6.68. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

AMGN vs. CYTK: A comparison of their P/E Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Forward P/E to Growth Ratio

AMGN

7.57

Drug Manufacturers - General Industry

Max: 3.10
Q3: 3.09
Median: 2.72
Q1: 2.18
Min: 1.02

AMGN’s Forward PEG Ratio of 7.57 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.

CYTK

11.70

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

CYTK’s Forward PEG Ratio of 11.70 is exceptionally high for the Biotechnology industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.

AMGN vs. CYTK: A comparison of their Forward PEG Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Price-to-Sales Ratio

AMGN

4.70

Drug Manufacturers - General Industry

Max: 6.47
Q3: 4.47
Median: 3.53
Q1: 1.96
Min: 0.41

AMGN’s P/S Ratio of 4.70 is in the upper echelon for the Drug Manufacturers - General industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

CYTK

215.39

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

With a P/S Ratio of 215.39, CYTK trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

AMGN vs. CYTK: A comparison of their P/S Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Price-to-Book Ratio

AMGN

25.85

Drug Manufacturers - General Industry

Max: 7.80
Q3: 7.80
Median: 5.30
Q1: 4.06
Min: 1.08

The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.

CYTK

-15.42

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

AMGN vs. CYTK: A comparison of their P/B Ratio against their respective Drug Manufacturers - General and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	AMGN	CYTK
Price-to-Earnings Ratio (P/E, TTM)	27.04	-6.68
Forward PEG Ratio (TTM)	7.57	11.70
Price-to-Sales Ratio (P/S, TTM)	4.70	215.39
Price-to-Book Ratio (P/B, TTM)	25.85	-15.42
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	14.69	-10.11
EV-to-EBITDA (TTM)	16.88	-9.41
EV-to-Sales (TTM)	6.12	252.72